Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Fineline Cube Jan 22, 2026
Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026
Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026
Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Drug

Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer

Fineline Cube Jan 22, 2026
Company Deals Drug

Baheal Partners with Jiluntai for Commercialization of Technetium-99m-labeled Imaging Agent

Fineline Cube Apr 24, 2025

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) has entered into a...

Company

PingAn Good Doctor Reports Q1 2025 Revenue Growth and Net Profit Turnaround

Fineline Cube Apr 24, 2025

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company Medical Device

MicroPort MedBot Gains NMPA Clearance for Toumai’s Remote Surgery Across Departments

Fineline Cube Apr 24, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced receiving clearance from China’s National...

Company Deals

QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb

Fineline Cube Apr 24, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has entered into a licensing agreement with...

Company

Roche Unveils $50 Billion Five-Year US Investment Plan to Expand Manufacturing and R&D

Fineline Cube Apr 23, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced a five-year investment plan totaling...

Company Deals

China Medical System Announces Spin-off of Dermavon for HKEX IPO

Fineline Cube Apr 23, 2025

China Medical System Holdings Limited (CMS; HKG: 0867) has announced the spin-off of its dermatology-focused...

Company Drug

BMS’s Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia

Fineline Cube Apr 23, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) has announced top-line results from the Phase III ARISE trial...

Company Drug

CSPC Gains NMPA Approval for Phase III Trial of Prusogliptin/Metformin FDC

Fineline Cube Apr 23, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured approval from the National Medical Products...

Company Drug

CSPC Pharmaceutical Gains FDA IND Clearance for JMT203 in Cancer Cachexia

Fineline Cube Apr 23, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) has obtained Investigational New Drug (IND) clearance from...

Company Drug

Grand Pharma Secures NMPA Approval for Fluticasone Nasal Spray

Fineline Cube Apr 23, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has obtained marketing authorization from China’s National...

Company Drug

Biokin Receives NMPA Approval for CD33 ADC in AML Trial

Fineline Cube Apr 23, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...

Company Deals

Fujifilm Diosynth Secures $3 Billion US Manufacturing Pact with Regeneron

Fineline Cube Apr 23, 2025

FUJIFILM Diosynth Biotechnologies (FDB), a leading global contract development and manufacturing organization (CDMO) specializing in...

Company Deals

Hotgen Biotech Injects RMB 300 Million into Subsidiary Sungen Bio for Biologic R&D

Fineline Cube Apr 23, 2025

China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic capital injection plan, partnering...

Policy / Regulatory

NMPA Issues 91st Batch of Reference Standards for Generic Drug Quality Evaluation

Fineline Cube Apr 23, 2025

The National Medical Products Administration (NMPA) has released the 91st batch of reference standards for...

Company Deals

United InnoMed Closes RMB 100 Million Series B+ Funding for Heart Failure Devices

Fineline Cube Apr 23, 2025

Shanghai-based United InnoMed, a developer of Class III active implantable medical devices, has closed a...

Company Medical Device

Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment

Fineline Cube Apr 23, 2025

Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has...

Company Deals

JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process

Fineline Cube Apr 23, 2025

China-based JW Therapeutics (HKG: 2126), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and...

Drug

iMBIORAY Gains NMPA Approval for Phase IITrial of IBR854 in Advanced RCC

Fineline Cube Apr 23, 2025

Hangzhou-based cancer immunotherapy specialist iMBIORAY has received approval from China’s National Medical Products Administration (NMPA)...

Company Drug

Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment

Fineline Cube Apr 23, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib...

Company Deals

Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines

Fineline Cube Apr 23, 2025

China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a...

Posts pagination

1 … 119 120 121 … 612

Recent updates

  • AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication
  • HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod
  • Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe
  • Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer
  • Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Company Medical Device

HeartCare Medical’s Intracranial Drug‑Eluting Stent Gets NMPA Filing Nod

Company Medical Device

Abbott’s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe

Company Drug

Lilly’s Sofetabart Wins FDA Breakthrough Status for Platinum‑Resistant Ovarian Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.